13F Holdings
中文EN

AEON AEON Biopharma, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue————
R&D expense$4.09M$14.18M$34.75M—
SG&A expense$12.21M$13.64M$13.68M—
Operating income-$12.80M$72.98M-$48.43M-$1.94M
Pretax income-$39.22M$42.01M-$52.56M$8.20M
Income tax$0$0$0—
Net income-$39.22M$42.01M-$52.56M$8.20M
EBITDA-$12.72M$73.08M-$48.36M—
EPS (basic)-3.9577.74-0.38—
EPS (diluted)-3.9572.93-0.38—
Weighted avg. shares (diluted)9.92M575,945138.85M—
Balance sheet
Cash & equivalents$3.01M$13,000$9.75M$5.13M
Current assets$3.40M$1.59M$9.84M$835,224
PP&E, net$162,000$235,000$431,000—
Total assets$5.56M$3.14M$10.78M$276.95M
Current liabilities$6.90M$14.15M$82.57M$834,585
Total liabilities$60.59M$31.71M$143.24M$17.88M
Shareholders' equity-$55.03M-$28.57M-$287.50M-$16.93M
Shares outstanding12.11M555,511138.83M—
Cash flow statement
Operating cash flow-$17.31M-$20.29M-$35.58M-$1.49M
Capital expenditure$4,000—$306,000—
Free cash flow-$17.31M—-$35.89M—
Investing cash flow-$4,000—-$306,000-$276.00M
Financing cash flow$20.30M$15.15M$40.51M$277.99M
Depreciation & amortization$78,000$97,000$68,000—
Stock-based compensation$5.32M$6.25M$5.89M—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.